Medications

Industry executives: Profits drive rising prices for MS drugs

U.S. Medicare patients with multiple sclerosis often pay, on average, nearly $7,000 out of pocket to treat their condition each year. And, even though drug companies have provided no new treatment breakthroughs, the price ...

Medications

New opioid library unveiled to help address epidemic

A new curated library, activated today, provides a centralized toolkit for policymakers, patients and health care professionals working to address the nation's opioid epidemic.

Health

Doctors' group calls for ban on most vaping products

(HealthDay)—The American Medical Association (AMA) is calling for a ban on all e-cigarettes and vaping products not approved by the U.S. Food and Drug Administration to help people quit smoking tobacco cigarettes.

Medical economics

Brand drug discount cards increase private insurer costs by 46%

Discount cards for brand-name drugs provided to patients increased private insurer costs by 46% and varied in their impact on out-of-pocket payments by patients, found new research in CMAJ (Canadian Medical Association Journal).

Alzheimer's disease & dementia

Biogen reanalyzes studies, presses ahead on Alzheimer's drug

Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.

page 31 from 40